Overview
Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition (hypertension, prediabetes, sleep apnea, etc.).
Treatment
Weekly injection, slow escalation, indefinite treatment for maintenance. Insurance coverage variable — Clindle helps navigate.
When to book a visit
Book to assess eligibility and coverage.
Book online today